CORT Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Corcept Therapeutics Incorporated Securities Lawsuit -- The Gross Law Firm

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against Corcept Therapeutics Incorporated (NASDAQ: CORT) for allegedly making false statements regarding the FDA's feedback on their drug relacorilant, which may have misled investors [2][4]. Group 1: Allegations and Legal Context - The class period for the lawsuit is defined as October 31, 2024, to December 30, 2025 [2]. - The complaint alleges that Corcept concealed concerns from the FDA regarding the adequacy of the relacorilant program for treating hypertension in patients with hypercortisolism, including issues with the GRACE study design [2]. - Defendants reportedly made materially false or misleading statements about their interactions with the FDA and the likelihood of NDA approval for relacorilant [2]. Group 2: Shareholder Actions and Deadlines - Shareholders who purchased CORT shares during the class period are encouraged to register for potential lead plaintiff appointment, with a deadline set for April 21, 2026 [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. - Participation in the case incurs no cost or obligation for shareholders [3]. Group 3: Law Firm's Mission and Commitment - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, emphasizing the importance of responsible corporate behavior [4]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated the company's stock price [4].